Csi 107
Alternative Names: Csi-107Latest Information Update: 03 Sep 2024
At a glance
- Originator Curigin
- Class Antifibrotics; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cystic fibrosis; Pulmonary fibrosis
Most Recent Events
- 03 Sep 2024 Discontinued for Cystic fibrosis in South Korea (Parenteral) (Curigin pipeline, September 2024)
- 03 Sep 2024 Discontinued for Pulmonary fibrosis in South Korea (Parenteral) (Curigin pipeline, September 2024)
- 23 Jun 2023 Early research in Cystic fibrosis in South Korea (Parenteral) (Curigin pipeline, June 2023)